A phase II open-label study with ARQ 197 administered orally and twice daily as monotherapy
in patients with previously treated advanced/recurrent gastric cancer. The primary endpoint
is disease control and the secondary efficacy endpoints include antitumor effect (tumor
response), progression-free survival and overall survival. The pharmacokinetic profile and
the safety profile are also evaluated.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.